Exceptional response to afatinib in a patient with persistent G719A <i>EGFR</i>-mutant NSCLC.

Kulkarni, Amit A; Fujioka, Naomi; Reinhardt, Lucia; Patel, Manish R; Kratzke, Robert A

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC.

Kulkarni, Amit A; Fujioka, Naomi; Reinhardt, Lucia; Patel, Manish R; Kratzke, Robert A.

Afiliación

Kulkarni AA; Department of Medicine, Division of Hematology, Oncology & Transplantation, University of Minnesota, MN 55455, USA.
Fujioka N; Department of Medicine, Division of Hematology, Oncology & Transplantation, University of Minnesota, MN 55455, USA.
Reinhardt L; Department of Medicine, Division of Hematology, Oncology & Transplantation, University of Minnesota, MN 55455, USA.
Patel MR; Department of Medicine, Division of Hematology, Oncology & Transplantation, University of Minnesota, MN 55455, USA.
Kratzke RA; Department of Medicine, Division of Hematology, Oncology & Transplantation, University of Minnesota, MN 55455, USA.

Lung Cancer Manag ; 11(1): LMT54, 2022 Mar.

Article en En | MEDLINE | ID: mdl-35463918

Palabras clave

EGFR mutation; NSCLC; afatinib; compound mutations; liquid biopsy; mutations; next-generation sequencing; osimertinib; rare mutations; uncommon tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Lung Cancer Manag Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google